Efficacy and Safety of Ecklonia cava Kjellman Extract Complex in Respiratory Health: A Randomized, Double‐Blind, Placebo‐Controlled, Multicenter Clinical Trial
Abstract
ABSTRACT Industrialization, air pollution, and respiratory infections have highlighted the importance of maintaining respiratory health. Ecklonia cava Kjellman (EC) has anti‐inflammatory, antioxidative, and anti‐allergic effects and therapeutic potential for respiratory symptoms. We evaluated the efficacy and safety of Ecklonia cava Kjellman extract complex (EEC), composed of EC and Chrysanthemum indicum Linnaeus ( C. indicum ) extract, in respiratory health. A randomized, double‐blind, placebo‐controlled, multicenter clinical trial was conducted. Participants (n = 106) were randomly allocated to the EEC and placebo groups at a 1:1 ratio and administered EEC or placebo twice daily for 12 weeks, with four visits (screening and weeks 0, 6, and 12). Breathlessness, cough, and sputum scale (BCSS), pulmonary function test (forced vital capacity (FVC), forced expired volume in 1 s (FEV1), and FEV1/FVC), St. George's respiratory questionnaire (SGRQ), visual analogue scale (VAS), and modified Medical Research Council dyspnea scale (mMRC) were assessed. BCSS (total, breathlessness, and sputum scores), FEV1, and VAS (cough and sputum) were significantly improved in the EEC group compared with the placebo group. No significant differences in SGRQ and mMRC between the groups. Safety assessments showed no severe adverse events or clinically significant changes. Given the established pharmacological mechanisms of EC, including its anti‐inflammatory, antioxidative, anti‐allergic, and…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 106 participants or records.
Read the paper
Related studies
- Antioxidant efficacy and the upregulation of Nrf2-mediated HO-1 expression by (+)-lariciresinol, a lignan isolated from Rubia philippinensis, through the activation of p38
- Anti-influenza virus activity of green tea by-products in vitro and efficacy against influenza virus infection in chickens
- Therapeutic Potential of Mesenchymal Stem Cells (MSCs) and MSC-Derived Extracellular Vesicles for the Treatment of Spinal Cord Injury
- The intratumoral administration of ferucarbotran conjugated with doxorubicin improved therapeutic effect by magnetic hyperthermia combined with pharmacotherapy in a hepatocellular carcinoma model
- Enhanced anticancer efficacy of TRAIL-conjugated and odanacatib-loaded PLGA nanoparticles in TRAIL resistant cancer
- In vivo tracking of bioorthogonally labeled T-cells for predicting therapeutic efficacy of adoptive T-cell therapy
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.